

4/23/99

K991294

510(k) SUMMARY

(As required by 21 CFR 807.92(a))

A. Submitter Information:

Medi-Ject Corporation
161 Cheshire Lane, Suite 100
Minneapolis, MN 55441 USA

Phone: (612) 475-7700

Fax: (612) 476-1009

Contact Person: Peggy L. Holland

Date: April 9, 1999

B. Device Information:

Trade/Proprietary Name: Medi-Ject Corporation Medi-Jector Choice
Needle-Free Insulin Delivery System

Common Name: Fluid Injector

Classification Name: Non-electrically powered fluid injector
(880.5430)

Predicate Device: Medi-Jector Choice, K962956

Device Description: Needle-Free Insulin Delivery System

Intended Use: The device is sold over the counter for the
subcutaneous injection of U-100 insulin.

C. Comparison of Required Technological Characteristics:

This submission changes the labeling of the Medi-Jector Choice (K962956) to allow the device to be sold over the counter. No other significant changes have been made to the device design, function or intended use.

D. Summary of Nonclinical Tests:

None were performed in support of this submission. This request is for a labeling change only.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

APR 23 1999

Mr. Peggy L. Holland
Medi-Ject Corporation
161 Cheshire Lane, Suite 100
Minneapolis, Minnesota 55441

Re: K991294
Trade Name: Medi-Ject Corporation Medi-Jector Choice
Needle-Free Insulin Delivery System
Regulatory Class: II
Product Code: KZE
Dated: April 12, 1999
Received: April 15, 1999

Dear Ms. Holland

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of


Page 2 - Ms. Holland

the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Timothy A. Ulatowski
Director

Division of Dental, Infection Control,
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known):

Device Name: Medi-Jector Choice Needle-Free Insulin Delivery System

Indications for Use:

The over the counter Medi-Jector Choice Needle-Free Insulin Delivery System is intended for the subcutaneous injection of U-100 insulin. The injector is labeled as suitable for administration of 2 to 50 insulin units in a 0.5 unit increment.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Rafaela Crocetti
(Division Sign-Off)

Division of Dental, Infection Control,
and General Hospital Devices

510(k) Number K991294

NOT A
PRESCRIPTION
DEVICE